Efficacy and Safety of Oral Gonadotropin-Releasing Hormone Antagonist, Relugolix, in Endometriosis: A Meta-Analysis of Randomized Clinical Trials

Milene Vitória Sampaio Sobral, João Pedro Pereira dos Santos, Tânia Aparecida Alves Vilela, Rafaela da Cunha Pirolla, Fernando Augusto Barreiros, Marina Ayabe Gomes de Moraes
In: American Journal of Therapeutics · 2024 · vol. 32(3) , pp. e309–e312 · doi:10.1097/mjt.0000000000001842 · PMID:39773659 · W4404577679
OA: closed CC0 ⤵ 1 in-corpus citation
Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".
View at publisher → View on OpenAlex View on PubMed
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-12 ⓘ

This meta-analysis of randomized clinical trials evaluated the efficacy and safety of the oral gonadotropin-releasing hormone antagonist, relugolix, for treating endometriosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

Condition tags

endometriosis

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (21)

Cited by (1)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
unpaywall
last seen: 2026-10-13T06:25:51.201866+00:00
License: CC0 · commercial use OK